US biotech Celgene’s (Nasdaq: CELG) offer of a price cut and improved data on Imnovid (pomalidomide) has persuaded the UK’s National Institute for Health and Care Excellence (NICE) to change its stance on the drug.
The cost-effectiveness watchdog has published draft guidance recommending pomalidomide, which is called Pomalyst in the USA, in combination with dexamethasone, via the National Health Service (NHS) for people in England with relapsed and refractory multiple myeloma (RRMM).
"Since the removal of pomalidomide from the CDF, Celgene has worked with NICE to ensure that patients in England can access this medicine"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze